CoChat
Sign Up
Cited by 135

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial

Manchanda, Ranjit, Loggenberg, Kelly, Sanderson, Saskia, Burnell, Matthew, Wardle, Jane, Gessler, Sue, Side, Lucy, Balogun, Nyala, Desai, Rakshit, Kumar, Ajith, Dorkins, Huw, Wallis, Yvonne, Chapman, Cyril, Taylor, Rohan, Jacobs, Chris, Tomlinson, Ian, McGuire, Alistair, Beller, Uziel, Menon, Usha, Jacobs, Ian·2015·JNCI: Journal of the National Cancer Institute
DOI 10.1093/jnci/dju379PMC PMC4301703
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/dju379

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Consort flow chart for the study. BL = baseline; DNA = did not attend; FH = family history; FM = founder mutations; GC = genetic counseling; Neg = negative; Pos = positive; PS = population screening.
Figure 1. Consort flow chart for the study. BL = baseline; DNA = did not attend; FH = family history; FM = founder mutations; GC = genetic counseling; Neg = negative; Pos = positive; PS = population screening.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 42

  1. Antoniou, 2005, Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies, J Med Genet, 42, 602, 10.1136/jmg.2004.024133 · DOI
  2. Chen, 2007, Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol, 25, 1329, 10.1200/JCO.2006.09.1066 · DOI · Paper page
  3. Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336, 1401, 10.1056/NEJM199705153362001 · DOI
  4. Finkelman, 2012, Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers, J Clin Oncol, 30, 1321, 10.1200/JCO.2011.37.8133 · DOI
  5. Rebbeck, 2009, Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, J Natl Cancer Inst, 101, 80, 10.1093/jnci/djn442 · DOI · Paper page
  6. Evans, 2009, Risk reducing mastectomy: outcomes in 10 European centers, J Med Genet, 46, 254, 10.1136/jmg.2008.062232 · DOI
  7. Nelson, 2005, Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force, Ann Intern Med, 143, 362, 10.7326/0003-4819-143-5-200509060-00012 · DOI
  8. Rebbeck, 2004, Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 22, 1055, 10.1200/JCO.2004.04.188 · DOI · Paper page
  9. Hartge, 1999, The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews, Am J Hum Genet, 64, 963, 10.1086/302320 · DOI
  10. King, 2003, Breast and ovarian cancer risks because of inherited mutations in BRCA1 and BRCA2, Science, 302, 643, 10.1126/science.1088759 · DOI · Paper page
  11. Moller, 2007, Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers, Eur J Cancer, 43, 1713, 10.1016/j.ejca.2007.04.023 · DOI
  12. Sivell, Cancer genetic risk assessment for individuals at risk of familial breast cancer, Cochrane Database Syst Rev, 2007, CD003721
  13. Zigmond, 1983, The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x · DOI · Paper page
  14. Gandek, 1998, Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality-of-life Assessment, J Clin Epidemiol, 51, 1171, 10.1016/S0895-4356(98)00109-7 · DOI · Paper page
  15. Cella, 2002, A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire, Health Psychol, 21, 564, 10.1037/0278-6133.21.6.564 · DOI
  16. UKFOCSS, (2007), United Kingdom Familial Ovarian Cancer Screening Study, Institute for Women’s Health
  17. Menon, 2009, Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), Lancet Oncol, 10, 327, 10.1016/S1470-2045(09)70026-9 · DOI
  18. Schlich-Bakker, 2006, A literature review of the psychological impact of genetic testing on breast cancer patients, Patient Educ Couns, 62, 13, 10.1016/j.pec.2005.08.012 · DOI
  19. Meiser, 2002, Psychological impact of genetic testing in women from high-risk breast cancer families, Eur J Cancer, 38, 2025, 10.1016/S0959-8049(02)00264-2 · DOI
  20. Smith, 1999, Familial context of genetic testing for cancer susceptibility: moderating effect of siblings’ test results on psychological distress one to two weeks after BRCA1 mutation testing, Cancer Epidemiol Biomarkers Prev, 8, 385
  21. Metcalfe, 2010, Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2, Clin Genet, 78, 411, 10.1111/j.1399-0004.2010.01499.x · DOI
  22. Andrews, 2004, Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study, Genet Test, 8, 240, 10.1089/gte.2004.8.240 · DOI
  23. Friedman, 1999, Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim, Genet Med, 1, 74, 10.1097/00125817-199903000-00003 · DOI
  24. Jenkinson, 1997, Development and testing of the UK SF-12 (short form health survey), J Health Serv Res Policy, 2, 14, 10.1177/135581969700200105 · DOI
  25. Beran, 2008, The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal?, Ann Behav Med, 36, 107, 10.1007/s12160-008-9060-9 · DOI
  26. Bahar, 2001, The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data, Cancer, 92, 440, 10.1002/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O · DOI
  27. Metcalfe, 2010, Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women, J Clin Oncol, 28, 387, 10.1200/JCO.2009.25.0712 · DOI
  28. Levy-Lahad, 2011, Identification of BRCA1/BRCA2 carriers by screening in the healthy population and its implications. In: American Society of Clinical Oncology, Annual meeting. 2011, J Clin Oncol, 29
  29. Weitzel, 2007, Limited family structure and BRCA gene mutation status in single cases of breast cancer, JAMA, 297, 2587, 10.1001/jama.297.23.2587 · DOI
  30. Hopper, 1999, Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study, Cancer Epidemiol Biomarkers Prev, 8, 741
  31. Peto, 1999, Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer, J Natl Cancer Inst, 91, 943, 10.1093/jnci/91.11.943 · DOI
  32. Hirsh-Yechezkel, 2003, Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel, Gynecol Oncol, 89, 494, 10.1016/S0090-8258(03)00152-5 · DOI
  33. de Sanjose, 2003, Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study, Int J Cancer, 106, 588, 10.1002/ijc.11271 · DOI
  34. Kang, 2006, Evaluation of models to predict BRCA germline mutations, Br J Cancer, 95, 914, 10.1038/sj.bjc.6603358 · DOI
  35. Marroni, 2004, Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations, J Med Genet, 41, 278, 10.1136/jmg.2003.013623 · DOI
  36. Barcenas, 2006, Assessing BRCA carrier probabilities in extended families, J Clin Oncol, 24, 354, 10.1200/JCO.2005.02.2368 · DOI
  37. Antoniou, 2008, Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics, J Med Genet, 45, 425, 10.1136/jmg.2007.056556 · DOI
  38. Kerlikowske, 2003, Evaluation of abnormal mammography results and palpable breast abnormalities, Ann Internal Med, 139, 274, 10.7326/0003-4819-139-4-200308190-00010 · DOI
  39. Chatterjee, 2006, Case-control and case-only designs with genotype and family history data: estimating relative risk, residual familial aggregation, and cumulative risk, Biometrics, 62, 36, 10.1111/j.1541-0420.2005.00442.x · DOI
  40. Chatterjee, 2001, Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study, Genet Epidemiol, 21, 123, 10.1002/gepi.1022 · DOI
  41. Chatterjee, 2001, A marginal likelihood approach for estimating penetrance from kin-cohort designs, Biometrics, 57, 245, 10.1111/j.0006-341X.2001.00245.x · DOI
  42. Shendure, 2008, Next-generation DNA sequencing, Nat Biotechnol, 26, 1135, 10.1038/nbt1486 · DOI · Paper page

Cited by

Sorted by citations

See all 135

Metadata

Authors
Manchanda, R., Loggenberg, K., Sanderson, S., Burnell, M., Wardle, J., Gessler, S., Side, L., Balogun, N., Desai, R., Kumar, A., Dorkins, H., Wallis, Y., Chapman, C., Taylor, R., Jacobs, C., Tomlinson, I., McGuire, A., Beller, U., Menon, U., & Jacobs, I.
Venue
JNCI: Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Published
2014-11-28
Volume
107
Issue
1
ISSN
  • 1460-2105
  • 0027-8874
DOI
10.1093/jnci/dju379
PMC
PMC4301703
Cited by
135
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review